Showing 1236 results
-
Ad-hoc Releases /Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
-
Press Release /First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
-
Press Release /Novartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
-
Ad-hoc Releases /Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…
-
Ad-hoc Releases /Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
-
Ad-hoc Releases /Chiffre d’affaires net des activités poursuivies1 en hausse de 3% (tcc2, +3% USD): Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto (+44%…
-
Press Release /Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
-
Press Release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently…
-
Press Release /Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and…
-
Ad-hoc Releases /The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related…